Fennec Pharmaceuticals Inc is experiencing a slight dip in its stock price this week, despite some positive news.
Fennec Pharmaceuticals Inc (FRX.TO) has seen a 1.90% decrease over the past week, closing at C$13.85. While recent headlines highlight the company's growth and financial performance, the market's reaction seems muted, with trading volumes significantly below average. Let’s take a closer look at the latest developments and technical indicators surrounding Fennec Pharmaceuticals.
Investor takeaway: Investors should keep Fennec's recent financial results and ongoing clinical developments in mind while considering the current price action and trading volume.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$484.58M
52W high
$15.48
52W low
$7.59
1W change
-1.90%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 570.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+570.8% Upside
Current Price
C$13.95
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
48.4%
Annualized
90-Day Vol
82.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.81 | C$12.53 – C$17.50 |
| 60 trading days | C$15.71 | C$12.41 – C$19.90 |
| 90 trading days | C$16.68 | C$12.48 – C$22.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Fennec Pharmaceuticals Reports 50% Year-Over-Year Revenue Growth
The company reported net product sales of $44.6 million for the full year 2025, reflecting strong demand for its leading product, PEDMARK®.
Bull case
Fennec's recent announcements of record revenues and positive clinical trial results indicate strong potential for future growth, especially with the increasing sales of PEDMARK®.
Bear case
The recent decline in stock price and low trading volume may signal investor uncertainty or profit-taking, which could impact short-term performance.
Recent Performance
Advertisement
Fennec Pharmaceuticals closed at C$13.85, marking a 1D change of 0.00%. Over the past week, the stock has decreased by 1.90%, while it has dropped 9.53% over the last month. Year-to-date, the stock has gained 34.01%, showing a robust performance earlier in the year.
Company News and Developments
Fennec Pharmaceuticals recently reported impressive financial results, showcasing record annual revenue with net product sales of $44.6 million, a 50% increase year-over-year. Additionally, the company announced positive topline results from a clinical study of PEDMARK® in Japan. However, there haven't been any major announcements this week that would significantly impact stock performance.
Technical Picture
Currently, Fennec Pharmaceuticals trades near its 50-day moving average of C$13.91, slightly below by 0.4%. The stock is well above its 200-day moving average of C$11.38, reflecting a 21.7% increase. The 52-week range for the stock spans from C$7.59 to C$15.48, indicating it is currently trading at 79% of its range. The stock's beta of 1.07 suggests it is slightly more volatile than the broader market. Recent trading volume stands at 125 shares, which is significantly lower than the 20-day average volume of 331 shares, indicating increased interest despite the price decline.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
